223 related articles for article (PubMed ID: 19298938)
1. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
[TBL] [Abstract][Full Text] [Related]
2. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
[TBL] [Abstract][Full Text] [Related]
3. Proliferation signal inhibitors and cardiac allograft vasculopathy.
Raichlin E; Kushwaha SS
Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
[TBL] [Abstract][Full Text] [Related]
4. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
Chapman JR; Valantine H; Albanell J; Arns WA; Campistol JM; Eisen H; Frigerio M; Lehmkuhl H; Marcen R; Morris R; Nashan B; Pascual J; Pohanka E; Segovia J; Zuckermann A
Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
[TBL] [Abstract][Full Text] [Related]
5. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
6. Clinical recommendations for the use of everolimus in heart transplantation.
Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
8. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV
Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515
[TBL] [Abstract][Full Text] [Related]
11. The University of California at Los Angeles heart transplantation experience.
Kobashigawa JA; Laks H; Wu G; Patel J; Moriguchi J; Hamilton M; Fonarow G; Fishbein M; Ardehali A
Clin Transpl; 2005; ():173-85. PubMed ID: 17424734
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prophylaxis of cardiac allograft vasculopathy.
Wang SS
Transplant Proc; 2008 Oct; 40(8):2609-10. PubMed ID: 18929815
[TBL] [Abstract][Full Text] [Related]
13. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
14. Cardiac allograft vasculopathy: recent developments.
Schmauss D; Weis M
Circulation; 2008 Apr; 117(16):2131-41. PubMed ID: 18427143
[TBL] [Abstract][Full Text] [Related]
15. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
Zuckermann A; Wang SS; Epailly E; Barten MJ; Sigurdardottir V; Segovia J; Varnous S; Turazza FM; Potena L; Lehmkuhl HB
Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
[TBL] [Abstract][Full Text] [Related]
16. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
17. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
Lehmkuhl H; Ross H; Eisen H; Valantine H
Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
[TBL] [Abstract][Full Text] [Related]
18. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
19. [Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation].
Caillard S
Nephrol Ther; 2009 Dec; 5 Suppl 6():S379-84. PubMed ID: 20129449
[TBL] [Abstract][Full Text] [Related]
20. Immunology insights into cardiac allograft rejection.
Savasta M; Lentini S
Rev Cardiovasc Med; 2011; 12(2):e68-76. PubMed ID: 21796085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
